Fed Statement Keeps Rally Alive
Fed Statement Keeps Rally Alive
Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know
Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $13.91, moving +0.87% from the previous trading session.
MediaJel Acquires Potnt Agency, Adds Merida Capital's Thomas Harrison As Chairman
The company appointed Thomas Harrison, Senior Operating Partner at Merida Capital Partners, as Chairman of the Board. Before joining the company, Harrison was Chairman Emeritus of Omnicom Group Inc (NYSE:...
Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today
A new patent is generating excitement among investors for this clinical-stage biotech stock.
Zynerba Pharmaceuticals Rises Due to Patent News
Zynerba Pharmaceuticals Rises Due to Patent NewsZynerba PharmaceuticalsZynerba Pharmaceuticals (ZYNE) has risen 18.6% as of 10:40 AM EST on June 11. The stock has been among the top-performing stocks this...
Healthcare tops midday movers
Gainers: Jaguar Health (NASDAQ: JAGX ) +60% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +40% . TORM (NASDAQ: TRMD ) +20% . Rekor Systems, Inc. (REKR) +17% . Enzo Biochem, Inc. (NYSE: ENZ ) +17% ....
Zynerba Advances Cannabidiol Treatment With New Patent Win
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a company that focuses on treating rare and near-rare neuropsychiatric disorders through cannabinoid therapies, said Tuesday it received a new U.S. patent for...
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S....
Zynerba nabs new patent in U.S.; shares up 5% premarket
The USPTO has issued Zynerba Pharmaceuticals (NASDAQ: ZYNE ), Patent No. 10,314,792, titled Treatment of Autism Spectrum Disorder with Cannabidiol which includes claims directed to methods of treating...
Zynerba Pharmaceuticals: An Updated Investment Thesis
If two men on the same job agree all the time, then one is useless. If they disagree all the time, both are useless . Darryl F. Zanuck Few stocks have been as volatile recently as Zynerba Pharmaceuticals...
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions such as Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).
Our goal is to advance the science of therapeutic cannabinoids, and to improve the lives of patients battling severe neuropsychiatric conditions including Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).
Our approach is to utilize our pharmaceutically-manufactured, penetration-enhanced transdermal cannabinoid product candidate to modulate pathways in the central nervous system that, when disrupted, cause certain neurological diseases. By doing so, we hope to provide new treatment options for patients battling certain rare neuropsychiatric diseases.